These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29575009)

  • 1. The efficacy of fluoxetine in BMS-A cross-over study.
    Zoric B; Jankovic L; Kuzmanovic Pficer J; Zidverc-Trajkovic J; Mijajlovic M; Stanimirovic D
    Gerodontology; 2018 Jun; 35(2):123-128. PubMed ID: 29575009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study.
    Maina G; Vitalucci A; Gandolfo S; Bogetto F
    J Clin Psychiatry; 2002 Jan; 63(1):38-43. PubMed ID: 11838624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dubious effect of milnacipran for the treatment of burning mouth syndrome.
    Sugimoto K
    Clin Neuropharmacol; 2011; 34(4):170-3. PubMed ID: 21738026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of moclobemide in burning mouth syndrome: a nonrandomized, open-label study.
    Pekiner FN; Gumru B; Ozbayrak S
    J Orofac Pain; 2008; 22(2):146-52. PubMed ID: 18548844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychiatric disorders in burning mouth syndrome.
    de Souza FT; Teixeira AL; Amaral TM; dos Santos TP; Abreu MH; Silva TA; Kummer A
    J Psychosom Res; 2012 Feb; 72(2):142-6. PubMed ID: 22281456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anxiety, depression, and pain in burning mouth syndrome: first chicken or egg?
    Schiavone V; Adamo D; Ventrella G; Morlino M; De Notaris EB; Ravel MG; Kusmann F; Piantadosi M; Pollio A; Fortuna G; Mignogna MD
    Headache; 2012 Jun; 52(6):1019-25. PubMed ID: 22607629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temperament and character profiles of patients with burning mouth syndrome.
    Tokura T; Kimura H; Ito M; Nagashima W; Sato N; Kimura Y; Arao M; Aleksic B; Yoshida K; Kurita K; Ozaki N
    J Psychosom Res; 2015 May; 78(5):495-498. PubMed ID: 25796514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interoceptive accuracy is related to the psychological mechanisms of the burning mouth syndrome: a cross-sectional study.
    Yoshino A; Otsuru N; Doi M; Maekawa T; Sasaoka T; Yamawaki S
    BMC Oral Health; 2022 Jul; 22(1):297. PubMed ID: 35854344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low regional cerebral blood flow in burning mouth syndrome patients with depression.
    Liu BL; Yao H; Zheng XJ; Du GH; Shen XM; Zhou YM; Tang GY
    Oral Dis; 2015 Jul; 21(5):602-7. PubMed ID: 25677983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
    Bennie EH; Mullin JM; Martindale JJ
    J Clin Psychiatry; 1995 Jun; 56(6):229-37. PubMed ID: 7775364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials.
    Judge R; Plewes JM; Kumar V; Koke SC; Kopp JB
    J Clin Psychopharmacol; 2000 Dec; 20(6):666-72. PubMed ID: 11106139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
    Sheehan DV; Nemeroff CB; Thase ME; Entsuah R;
    Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial.
    Macías-Cortés Edel C; Aguilar-Faisal L; Asbun-Bojalil J
    Trials; 2013 Apr; 14():105. PubMed ID: 23782520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
    Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbiities, treatment and outcome.
    Mitsikostas DD; Ljubisavljevic S; Deligianni CI
    J Headache Pain; 2017 Dec; 18(1):40. PubMed ID: 28357703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.